Immuron achieves record travelan® sales

Highlights: travelan® sales ytd jan 2024 of $2.7 million exceed peak full year fy20 sales of $2.5 million australian travelan® ytd jan 2024 sales $2.1 million usa travelan® ytd jan 2024 sales $0.6 million canadian sales recommenced through mckesson melbourne, australia, feb. 13, 2024 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian based and globally integrated biopharmaceutical company is pleased to announce record sales (unaudited net sales) of travelan®, an over-the-counter immune supplement that targets pathogenic bacteria and the toxins they produce in the gastrointestinal (gi) tract. australia sales of travelan® increased to aud $2.1 million ytd jan 2024 compared to aud $0.3 million ytd jan 2023.
IMRN Ratings Summary
IMRN Quant Ranking